Venus Medtech completes China enrollment for Venus-PowerX pivotal TAVR trial

The PREVAILS study supports simultaneous filings for CE mark in Europe and NMPA approval in China for the company’s dry-valve, fully retrievable system.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.